| Gene | Score gda | Association Type | Type | Original DB | Sentence supporting the association | PMID | PMID Year | ||||
|---|---|---|---|---|---|---|---|---|---|---|---|
|
0.060 | Biomarker | disease | BEFREE | These biological tests assessed can be classified as: (i) proven to be effective at diagnosing LB and already in use (CXCL-13 for neuroborreliosis), but not enough to be standardized; (ii) not yet used routinely, requiring further clinical evaluation (CCL-19, OspA and interferon-α); (iii) uncertain LB diagnostic efficacy because of controversial results and/or poor methodological quality of studies evaluating them (lymphocyte transformation test, interferon-γ, ELISPOT); (iv) unacceptably low sensitivity and/or specificity (CD57<sup>+</sup> natural killer cells and rapid diagnostic tests); and (v) possible only for research purposes (microscopy and xenodiagnoses). | 31306793 | 2020 | ||||
|
0.060 | GeneticVariation | disease | BEFREE | The variables age, sex, facial nerve palsy, generalized inflammation symptoms (fever, headache, neck-stiffness and/or fatigue), duration of symptoms, <i>Borrelia</i> antibodies in CSF, <i>Borrelia</i> antibody index (AI), CSF white blood cells (WBC), CSF protein and detection of the genospecies <i>Borrelia garinii</i> by PCR were included in simple and multivariable regression analyses to study the associations with the CXCL13 level. | 31573360 | 2020 | ||||
|
0.060 | Biomarker | disease | BEFREE | Pleocytosis and increased protein and CXCL13 values in the CSF suggest LB as the cause of facial palsy. | 31634297 | 2019 | ||||
|
0.060 | Biomarker | disease | BEFREE | Neuroborreliosis and acute encephalopathy: The use of CXCL13 as a biomarker in CNS manifestations of Lyme borreliosis. | 29246814 | 2018 | ||||
|
0.060 | Biomarker | disease | BEFREE | The CXCL13 concentration positively correlated with CSF lymphocyte/monocyte count and Borrelia-specific intrathecal antibody index (p < 0.05). | 29705691 | 2018 | ||||
|
0.060 | Biomarker | disease | BEFREE | CSF CXCL13 is a sensitive and specific marker of neuroborreliosis in individuals with Borrelia-specific intrathecal antibody production. | 29340592 | 2018 |